IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: A long term observational study

Annals of the Rheumatic Diseases

Volumn 64, Issue 7, 2005, Pages 1015-1021

  Stummvoll, G H ^a   Aringer, M ^a   Smolen, J S ^a   Schmaldienst, S ^a   Jimenez Boj E ^a   Horl W H ^a   Graninger, W B ^a   Derfler, K ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; ERYTHROPOIETIN; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IRON DERIVATIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RANITIDINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMUNOADSORPTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; OBSERVATION; PRIORITY JOURNAL; PROTEINURIA; PSEUDOMONAS; SCORING SYSTEM; SEPTICEMIA; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANALYSIS OF VARIANCE; AZATHIOPRINE; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; PATIENT SELECTION; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 21344469093     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.029660     Document Type: Article

References (57)

1. Fritzler MJ, Elkon KB. Autoantibodies in SLE. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. In: Rheumatology. 3rd ed. Edinburgh: Mosby, 2003:1337-46.
2. Ebling FM, Hahn BH. Pathogenic subsets of antibodies to DNA. Int Rev Immunol 1989;5:79-95.
3. Maddison PJ, Reichlin M. Deposition of antibodies to a soluble cytoplasmic antigen in the kidneys of patients with systemic lupus erythematosus. Arthritis Rheum 1979;22:858-63.
4. Ohnishi K, Ebling FM, Mitchell B, Singh RR, Hahn BH, Tsao BP. Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. Int Immunol 1994;6:817-30.
5. Raz E, Brezis M, Rosenmann E, Eilat D. Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J Immunol 1989;142:3076-82.
6. Madaio MP, Carlson J, Cataldo J, Ucci A, Migliorini P, Pankewycz O. Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J Immunol 1987;138:2883-89.
7. Houssiau FA, D'Cruz D, Vianna J, Hughes GR. Lupus nephritis: the significance of serological tests at the time of biopsy. Clin Exp Rheumatol 1991;9:345-9.
8. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193-9.
9. Austin HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-19.
10. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
11. Wallace DJ. Severe lupus. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. In: Rheumatology. 3rd ed. Edinburgh: Mosby, 2003:1419-25.
12. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
13. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996;39:1475-82.
14. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997;6:254-7.
15. Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 2004;13:366-71.
16. Boumpos DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
17. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326:1373-9.
18. Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis 1998;13:163-6.
19. Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998;41:414-20.
20. Wallace DJ. Apheresis for lupus erythematosus. Lupus 1999;8:174-80.
21. Blake JS, Butani L. TI-rapidly progressive lupus glomerulonephritis and concomitant microangiopathy in an adolescent. Lupus 2002;11:533-5.
22. Jones JV, Cumming RH, Bacon PA, Evers J, Fraser ID, Bothamley J, et al. TI-evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 1979;48:555-76.
23. Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Opin Hematol 2000;7:325-9.
24. Schneider KM. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Kidney Int Suppl 1998;64:S61-5.
25. Richter WO, Donner MG, Selmaier A, Hiller E, Schwandt P. Efficacy and safety of immunoglobulin apheresis. ASAIO J 1997;43:53-9.
26. Knöbl P, Derfler K, Korninger L, Kapiotis S, Jäger U, Maier-Dobersberger T, et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 1995;74:1035-8.
27. Tribl B, Knöbl P, Derfler K, Kapiotis S, Aspock G, Jäger U, et al. Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression. Ann Hematol 1995;71:199-203.
28. Gaubitz M, Seidel M, Kummer S, Schotte H, Perniok A, Domschke W, et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 1998;11:495-501.
29. Stummvoll GH, Aringer M, Jansen M, Smolen J, Derfler K, Graninger W. Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. Wien Klin Wochenschr 2004;116:716-24.
30. Palmer A, Cairns T, Dische F, Gluck G, Gjorstrup P, Parsons V, et al. Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 1991;6:536-42.
31. Schmaldienst S, Jansen M, Hollenstein U, Graninger W, Regele H, Hörl WH, et al. Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis. Am J Kidney Dis 2002;39:415-18.
32. Dittrich E, Schmaldienst S, Langer M, Jansen M, Hörl WH, Derfler K. Immunoadsorption and plasma exchange in pregnancy. Kidney Blood Press Res 2002;25:232-9.
33. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490-7.
34. Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999;26:504-7.
35. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus 2000;9:322-7.
36. Smolen JS. Clinical and serologic features: incidence and diagnostic approach. In: Smolen JS, Zielinski CC, eds. Systemic lupus erythemotosus. Berlin: Springer, 1987:171-96.
37. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
38. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
39. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, Steiner CW, et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002;11:102-8.
40. Vitali C, Bencivelli W, Mosca M, Carrai P, Sereni M, Bombardieri S. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J Rheumatol 1999;26:498-501.
41. Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus 1999;8:632-7.
42. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
43. Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, et al. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 1998;9:1709-15.
44. Schmaldienst S, Goldammer A, Spitzauer S, Derfler K, Hörl WH, Knobl P. Local anticoagulation of the extracorporeal circuit with heparin and subsequent neutralization with profamine during immunoadsorption. Am J Kidney Dis 2000;36:490-7.
45. Böhm M, Dorner T, Knebel F, Bruns A, Jochmann N, Baumann G. Longlasting effects of immunoadsorption in severe Sjögren's syndrome. Ann Rheum Dis 2004;63:214-15.
46. Jansen M, Schmaldienst S, Banyai S, Quehenberger P, Pabinger I, Derfler K, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001;112:91-7.
47. Julius U, Patzak A, Schaich M, Ehninger G, Kamin G. Immune thrombocytopenia, anemia and leukopenia during pregnancy. Successful therapy with extracorporeal immunoadsorption. Dtsch Med Wochenschr 1997;122:220-4.
48. Schmaldienst S, Mullner M, Goldammer A, Spitzauer S, Bonyai S, Hörl WH, et al. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford) 2001;40:513-21.
49. Staudt A, Schaper F, Stangl V, Plagemann A, Bohm M, Merkel K, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001;103:2681-6.
50. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
51. ACR. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004;50:3418-26.
52. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9.
53. Tylicki L, Rufkowski P, Renke M, Rufkowski B. Renoprotecfive effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation. Am J Nephrol 2002;22:356-62.
54. Wallace DJ. Apheresis for lupus erythematosus: state of the art. Lupus 2001;10:193-6.
55. Wei N, Klippel JH, Huston DP, Hall RP, Lawley TJ, Balow JE, et al. Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983;i:17-22.
56. Mistry-Burchardi N, Schonermarck U, Samtleben W. Apheresis in lupus nephritis. Ther Apher 2001;5:161-70.
57. Gladman DD, Hussain F, Ibanez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002;11:234-9.